Amanda Manoogian, PharmD, BCOP, Clinical Pharmacy Coordinator Specialty Pharmacy - Clinical Services (Partners Healthcare)

home / authors / amanda-manoogian-pharmd-bcop-clinical-pharmacy-coordinator-specialty-pharmacy-clinical-services-partners-healthcare

Articles

Oral Therapies for Hormone Receptor – Positive Breast Cancers

Oral Therapies for Hormone Receptor – Positive Breast Cancers

Amanda Manoogian, PharmD, BCOP, Clinical Pharmacy Coordinator Specialty Pharmacy - Clinical Services (Partners Healthcare)
December 23rd 2019

The recent development of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, as well as alpelisib (Piqray), a phosphoinositide 3-kinase (PI3K) inhibitor, has changed the way patients with HR-positive MBC are treated.

Read More

Latest Updated Articles

10 Pharmacy Quotes That Will Make You Rethink the Profession
Published: January 18th 2016 | Updated: October 18th 2024
10 Pharmacy Quotes That Will Make You Rethink the Profession
Gabapentin Differs From Pregabalin in Several Key Ways
Published: September 22nd 2015 | Updated: October 14th 2024
Gabapentin Differs From Pregabalin in Several Key Ways
Semaglutide injecting pen on a white background, macro. Needle macro - Image credit: artmim | stock.adobe.com
Published: October 17th 2024 | Updated: October 23rd 2024
Concerns Linger About GLP-1 Agonists Despite Their Popularity
Vial with pneumococcal disease vaccine and syringe for injection.
Published: October 21st 2024 | Updated: October 23rd 2024
Pneumococcal 21-Valent Conjugate Vaccine Generates Positive Response in Adults at Increased Risk of Disease
Myasthenia Gravis disease blood test in doctor hand
Published: October 21st 2024 | Updated: October 23rd 2024
Myasthenia Gravis Negatively Impacts Patients and Care Partners Through Clinical, Financial Burdens
FDA Approval, Stelara, Biosimilar | Image Credit: Calin - stock.adobe.com
Published: October 1st 2024 | Updated: October 23rd 2024
FDA Approves Ustekinumab-Aauz as Biosimilar for Stelara